Emmanuel Gyan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6057356/publications.pdf

Version: 2024-02-01

101 papers	4,573 citations	145106 33 h-index	120465 65 g-index
103 all docs	103 docs citations	103 times ranked	6538 citing authors

#	Article	IF	Citations
1	Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. Cancer Gene Therapy, 2022, 29, 1263-1275.	2.2	4
2	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood, 2022, 139, 1684-1693.	0.6	56
3	Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics, 2022, 14, 792.	2.0	0
4	Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. Scientific Reports, 2022, 12, .	1.6	1
5	Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study. Hematological Oncology, 2022, 40, 976-986.	0.8	2
6	A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood, 2021, 137, 2646-2656.	0.6	39
7	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood, 2021, 137, 751-762.	0.6	183
8	Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckmanâ€"Coulter DxH 800 Hematology Analyzer. Cancers, 2021, 13, 389.	1.7	11
9	Long-term outcome of imatinib 400â€‰mg compared to imatinib 600â€‰mg or imatinib 400â€‰mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia, 2021, 35, 2332-2345.	3.3	15
10	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. Bone Marrow Transplantation, 2021, 56, 1700-1709.	1.3	6
11	No survival improvement in patients with highâ€risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. British Journal of Haematology, 2021, 194, 635-638.	1.2	7
12	Intravenous highâ€dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An <scp>LOC</scp> network study. American Journal of Hematology, 2021, 96, 823-833.	2.0	18
13	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkinâ€™s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.. Journal of Clinical Oncology, 2021, 39, 7544-7544.	0.8	3
14	Megaloblastic anemia-related iron overload and erythroid regulators: a case report. Journal of Medical Case Reports, 2021, 15, 463.	0.4	2
15	Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition. Cancers, 2021, 13, 5699.	1.7	6
16	Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. Oncogene, 2020, 39, 1198-1212.	2.6	32
17	Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases. Annals of Hematology, 2020, 99, 229-239.	0.8	10
18	Involvement of GPx-3 in the Reciprocal Control of Redox Metabolism in the Leukemic Niche. International Journal of Molecular Sciences, 2020, 21, 8584.	1.8	8

#	Article	IF	Citations
19	High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers. Blood Advances, 2020, 4, 3550-3557.	2.5	38
20	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. Blood Advances, 2020, 4, 5322-5335.	2.5	8
21	Reactive oxygen species levels differentiate CD34 + human progenitors based on CD38 expression. Cytometry Part B - Clinical Cytometry, 2020, 98, 516-521.	0.7	3
22	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <scp>LYSA</scp> group. Hematological Oncology, 2020, 38, 446-455.	0.8	5
23	Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood, 2020, 135, 1811-1815.	0.6	17
24	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transplantation, 2020, 55, 1076-1084.	1.3	20
25	Meta-analysis of case-control studies to examine the relationship between occupational pesticide exposure and risk of acute myeloid leukemia.. Journal of Clinical Oncology, 2020, 38, 7540-7540.	0.8	0
26	Clonal hematopoiesis in the bone marrow and blood of healthy volunteers.. Journal of Clinical Oncology, 2020, 38, 7517-7517.	0.8	0
27	Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study. Blood, 2020, 136, 15-17.	0.6	0
28	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. Blood, 2020, 136, 12-13.	0.6	8
29	A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome. Science Translational Medicine, 2019, 11, .	5.8	55
30	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2366-2374.	2.0	3
31	Characteristics, combinations, treatments, and survival of second primary hematological neoplasm: a retrospective single-center cohort of 49 patients (Hemo2study). Annals of Hematology, 2019, 98, 2367-2377.	0.8	1
32	Less iron improves MDS haematopoiesis. British Journal of Haematology, 2019, 187, 11-12.	1.2	1
33	Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Advances, 2019, 3, 4271-4279.	2.5	19
34	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	1.7	17
35	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood, 2018, 132, 49-58.	0.6	130
36	Endogenous Metabolitesâ€Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity. Clinical Pharmacology and Therapeutics, 2018, 104, 687-698.	2.3	32

#	Article	IF	Citations
37	Prospective evaluation of the effect of deferasirox on hematologic response in transfusionâ€dependent patients with lowâ€risk <scp>MDS</scp> and iron overload. European Journal of Haematology, 2018, 101, 165-173.	1.1	7
38	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, The, 2018, 19, 747-757.	5.1	444
39	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood, 2018, 131, 174-181.	0.6	121
40	Benefits and pitfalls of pegylated interferon-Î±2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica, 2018, 103, 438-446.	1.7	50
41	Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report. Journal of Medical Case Reports, 2018, 12, 199.	0.4	6
42	Bendamustine and rituximab in elderly patients with lowâ€tumour burden follicular lymphoma. Results of the <scp>LYSA</scp> phase <scp>II BRIEF</scp> study. British Journal of Haematology, 2018, 183, 76-86.	1.2	14
43	n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activation. Pharmacological Research, 2018, 136, 45-55.	3.1	26
44	Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group. Blood, 2018, 132, 2846-2846.	0.6	0
45	Endogenous metabolites that are substrates of organic anion transporterâ€™s (OATs) predict methotrexate clearance. Pharmacological Research, 2017, 118, 121-132.	3.1	22
46	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology, 2017, 35, 552-560.	0.8	87
47	Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis. Stem Cells and Development, 2017, 26, 709-722.	1.1	39
48	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematology,the, 2017, 4, e35-e45.	2.2	33
49	Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. Oncotarget, 2017, 8, 41876-41889.	0.8	33
50	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget, 2016, 7, 85573-85583.	0.8	13
51	Midostaurin in Advanced Systemic Mastocytosis. New England Journal of Medicine, 2016, 374, 2605-2606.	13.9	54
52	Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network. Blood, 2016, 128, 785-785.	0.6	39
53	REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015018.	0.5	7
54	Longâ€term followâ€up and second malignancies in 487 patients with hairy cell leukaemia. British Journal of Haematology, 2014, 166, 390-400.	1.2	53

#	Article	IF	Citations
55	Could a citrus keep the haematologist away?. British Journal of Haematology, 2014, 166, 298-300.	1.2	1
56	An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leukemia Research Reports, 2014, 3, 58-61.	0.2	76
57	Urinary coproporphyrin <scp>I</scp>/(<scp>I</scp>â€‰+â€‰<scp>III</scp>) ratio as a surrogate for <scp>MRP2</scp> or other transporter activities involved in methotrexate clearance. British Journal of Clinical Pharmacology, 2014, 78, 329-342.	1.1	16
58	Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17Âyearsâ€™ experience in a single centre. Annals of Hematology, 2014, 93, 147-156.	0.8	6
59	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Annals of Hematology, 2014, 93, 233-242.	0.8	17
60	Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study. Blood, 2014, 124, 1321-1321.	0.6	2
61	High Efficiency and Tolerance of Temozolomide in Relapse/Refractory Primary Intra-Ocular Lymphoma (R/R PIOL). a Retrospective Multicentric Study from the LOC Network. Blood, 2014, 124, 3080-3080.	0.6	0
62	Mast Cell Disease and Blood Coagulation Abnormalities: Discussion on 14 Cases and Review of the Literature. Blood, 2014, 124, 2856-2856.	0.6	1
63	A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. Journal of Pharmaceutical and Biomedical Analysis, 2013, 83, 164-170.	1.4	6
64	High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Annals of Hematology, 2013, 92, 621-631.	0.8	40
65	Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. Journal of Clinical Oncology, 2013, 31, 2920-2926.	0.8	137
66	Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leukemia and Lymphoma, 2013, 54, 2399-2404.	0.6	25
67	Cardiac iron overload assessed by <scp>T</scp>2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. British Journal of Haematology, 2013, 162, 413-415.	1.2	29
68	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large <scp>B</scp>â€cell lymphoma in first relapse: results of the <scp>R</scp>â€<scp>NIMP GOELAMS</scp> study. British Journal of Haematology, 2013, 162, 240-249.	1.2	12
69	Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Annals of Oncology, 2013, 24, 2612-2618.	0.6	30
70	Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial. Journal of Clinical Oncology, 2013, 31, 104-110.	0.8	134
71	Efficacy and safety of pegylatedâ€interferon Î±â€2a in myelofibrosis: a study by the <scp>FIM</scp> and <scp>GEM</scp> French cooperative groups. British Journal of Haematology, 2013, 162, 783-791.	1.2	67
72	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica, 2013, 98, 881-887.	1.7	78

#	Article	IF	Citations
73	Flow Cytometric Quantification of All Phases of the Cell Cycle and Apoptosis in a Two-Color Fluorescence Plot. PLoS ONE, 2013, 8, e68425.	1.1	93
74	Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. Journal of Antimicrobial Chemotherapy, 2012, 67, 1493-1495.	1.3	29
75	Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas. Clinical Cancer Research, 2012, 18, 5203-5211.	3.2	210
76	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 2012, 97, 1085-1091.	1.7	94
77	Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood, 2012, 119, 1532-1542.	0.6	61
78	Epidermotropic secondary cutaneous involvement by relapsed angioimmunoblastic <scp>T</scp>â€cell lymphoma mimicking mycosis fungoides: a case report. Journal of Cutaneous Pathology, 2012, 39, 1119-1124.	0.7	12
79	Long-Term Follow-Up of Tandem High-Dose Therapy with Autologous Stem Cell Support for Adults with High-Risk Age-Adjusted International Prognostic Index Aggressive non-Hodgkin Lymphomas: A GOELAMS Pilot Study. Biology of Blood and Marrow Transplantation, 2011, 17, 935-940.	2.0	7
80	Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood, 2011, 118, 4338-4345.	0.6	104
81	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica, 2011, 96, 1128-1135.	1.7	99
82	Positron Emission Tomographyâ€"Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology, 2011, 29, 3194-3200.	0.8	176
83	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica, 2010, 95, 1350-1357.	1.7	36
84	MÃ©thylation etÂsyndromes myÃ©lodysplasiques. Hematologie, 2010, 16, 12-16.	0.0	0
85	Bone Marrow Mesenchymal Stromal Cells Regulate the Metabolism of H2O2 In Human Leukemic Cells.. Blood, 2010, 116, 1058-1058.	0.6	0
86	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood, 2009, 113, 995-1001.	0.6	144
87	Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. Leukemia, 2008, 22, 1864-1873.	3.3	27
88	Apoptotic pathways to death in myelodysplastic syndromes. Haematologica, 2008, 93, 1288-1292.	1.7	10
89	Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. Haematologica, 2007, 92, 1623-1630.	1.7	30
90	Caspase-8 prevents sustained activation of NF-ÎºB in monocytes undergoing macrophagic differentiation. Blood, 2007, 109, 1442-1450.	0.6	125

#	Article	IF	Citations
91	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. New England Journal of Medicine, 2007, 357, 1916-1927.	13.9	412
92	Reply to â€˜hRap1B-retro: a novel human processed Rap1B gene blurs the picture?â€™ by Zemojtel et al. Leukemia, 2006, 20, 146-147.	3.3	5
93	Mitochondria in hematopoiesis and hematological diseases. Oncogene, 2006, 25, 4757-4767.	2.6	85
94	Mutation in RAP1 is a rare event in myelodysplastic syndromes. Leukemia, 2005, 19, 1678-1680.	3.3	14
95	Pseudouveitis. Medicine (United States), 2004, 83, 223-232.	0.4	16
96	Rituximab therapy for HIV-associated Castleman disease. Blood, 2003, 102, 2786-2788.	0.6	152
97	Primary Central Nervous System Lymphoma in Immunocompetent Adults: Poor Results Mainly Associated with High Treatment Related Toxicities. Leukemia and Lymphoma, 2002, 43, 1819-1822.	0.6	7
98	Pit2 Assemblies at the Cell Surface Are Modulated by Extracellular Inorganic Phosphate Concentration. Journal of Virology, 2002, 76, 4304-4311.	1.5	38
99	p16 INK4a andp15INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood, 2001, 98, 244-246.	0.6	77
100	Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype. Leukemia, 2001, 15, 1054-1059.	3.3	8
101	Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy. The Hematology Journal, 2001, 2, 210-211.	2.0	14